信达生物制药集团何开杰等人在 Nature 子刊 Nature Cancer 上发表了题为:IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells 的研究论文。 该论文介绍了信达生物医药开发的抗PD-1/IL-2双特异性抗体融合蛋白(研发代号:IBI363)的部分早期临床前核心机制研究结果。
近日,来自美国Asher Biotherapeutics公司的Ivana M. Djuretic团队在Cancer Discovery杂志上发表了一篇题为IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity的文章,他们开发了一种CD8...
s=86 Kelly D. Moynihan,et al; IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity. Cancer Discov 2024; https://doi.org/10.1158/2159-8290.CD-23-1266 Paulien Kaptein,et al; CD8-targeted IL2 unleashes tu...
Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol. 2013 Jun 15;190(12):6230-8. doi: 10.4049/jimmunol.1201895. Epub 2013 May 15. PMID: 23677467. [8].Waldmann TA. The role of the multichain IL-2 receptor complex in the control of normal and malignant ...
2021年12月22日，Science Translational Medicine上背靠背发表两篇题为An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma和A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a ...
Combination of these two lymphokines could augment the antitumor activities of human PBMC greatly. These results suggest that these two lymohokines may be used as cancer therapeutie and prophylactic agents.沈泽荔何俊森中国癌症研究(英文版)
(TSTs) and exhibit better antitumor efficacy and safety than the ‘non-α’ counterpart (IL-2nα). Mechanistically, TSTs coexpress elevated CD25 and PD-1 and are more susceptible to stimulation by IL-2Rα-proficient agonists. Moreover, the antitumor efficacy of anti-PD-1 depends on ...
信达生物制药集团何开杰等人在 Nature 子刊 Nature Cancer 上发表了题为:IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells 的研究论文。 该论文介绍了信达生物医药开发的抗PD-1/IL-2双特异性抗体融合蛋白(研发代号:IBI363)的部分早期临床前核心机制研究结果...
参考文献 Eric J. Hsu et al,A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy ,Nat Commun . 2021 May 13;12(1):2768.
Intratumoral regulatory T (T) cell abundance associates with diminished antitumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high-affinity receptor subunit for interleukin (IL)-2, is a selective target for Tdepletion in mouse and human malignancies; however...